METHOD FOR INHIBITING THE GROWTH OF MYCOBACTERIUM TUBERCULOSIS BY USING CD13 RECEPTOR

• US 20120064624A1
• Filed: 06/20/2011
• Published: 03/15/2012
• Est. Priority Date: 09/14/2010
• Status: Active Grant

• Current Assignee: Mackay Memorial Hospital
• Original Assignee: Mackay Memorial Hospital
• Inventors: Lu, Yen-Ta, Tsai, I-Fang
• Granted Patent: US 8,491,894 B2
• Time in Patent Office: Days
• US Class Current: 435/372
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention discloses a method for inhibiting the growth of Mycobacterium tuberculosis, comprising: administering at least one selective binding agent such as an anti-CD13 antibody or a CD13 antagonist which can bind a CD13 receptor of a cell to inhibit infection of Mycobacterium tuberculosis. Administration of anti-CD13 antibody can reduce an expression level of the CD13 receptor, inhibit entry of Mycobacterium tuberculosis into monocytes, reduce survival of Mycobacterium tuberculosis in monocytes, and kill Mycobacterium tuberculosis effectively.

Claims

1. A method for inhibiting the growth of Mycobacterium tuberculosis, comprising:

administering at least one selective binding agent binding to a CD13 receptor to prevent a cell from infection by Mycobacterium tuberculosis.

2. The method according to claim 1, wherein the selective binding agent is an anti-CD13 antibody.

3. The method according to claim 2, wherein the anti-CD13 antibody is WM15 antibody.

4. The method according to claim 2, wherein the anti-CD13 antibody is WM47 antibody.

5. The method according to claim 1, wherein the selective binding agent is a CD13 antagonist.

6. The method according to claim 1, wherein the selective binding agent reduces an expression level of the CD13 receptor.

7. The method according to claim 2, wherein the anti-CD13 antibody reduces endocytic internalization of Mycobacterium tuberculosis which entry into the cell.

8. The method according to claim 2, wherein the anti-CD13 antibody reduces survival of Mycobacterium tuberculosis in the cell.

9. The method according to claim 2, wherein the anti-CD13 antibody is used in pre-treatment of the cell.

10. The method according to claim 2, wherein the anti-CD13 antibody is used after Mycobacterium tuberculosis infection of the cell.

11. The method according to claim 2, wherein the cell is a human monocyte.